We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novavax has announced that it will start a late-stage clinical trial of its investigational COVID-19 vaccine in the U.S. by the end of November. Read More
Pfizer CEO Albert Bourla announced Tuesday that the company won’t have the necessary phase 3 trial data required to submit its COVID-19 vaccine candidate for Emergency Use Authorization (EUA) this month, despite previous projections. Read More
AstraZeneca’s COVID-19 vaccine candidate, AZD1222, elicited immune responses in older coronavirus patients similar to ones generated in younger adults, lending more promise to a vaccine that’s seen as one of the leading contenders in the race to become the first approved COVID-19 vaccine. Read More
An Indian trial evaluating convalescent plasma as a COVID-19 treatment has found that the therapy failed to reduce progression to severe COVID-19 or death, leaving the Indian government skeptical about its viability, though medical experts say the treatment may still hold promise. Read More
CRISPR Therapeutics has reported positive results for a phase 1 study evaluating CTX110, its chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory nonHodgkin’s lymphoma in patients who have received at least two prior lines of therapy. Read More
Preliminary results show complete remission of advanced B-cell lymphoma in some participants, but one patient who received the treatment died. Read More